Factive tab. approved by KFDA as the fifth new drug in Korea

Published: 2002-12-30 07:00:00

Updated: 2002-12-30 07:00:00

The Korea Foood and Drug Administration (KFDA) said on December 27 that it approved LG Life Sciences's Factive tab.(gemifloxacin), a novel fluoroquinolone antibiotic with potent, broad-spectrum antimicrobial activity.

This was the fifth new drug approval by the KFDA, following SK Pharm's Sunpl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK